{"content":[{"text":"solid tumors in the pre-clinical setting. For more information, visit www.beyondair.net.","bbox":{"left":0.098039,"top":0.06867,"width":0.736012,"height":0.016926999999999998}},{"text":"Forward Looking Statements \n This press release contains “forward-looking statements” concerning inhaled nitric-oxide and \n the Company’s LungFit™ product, including statements with regard to potential regulatory \n developments, the potential impact on patients and anticipated benefits associated with its \n use. Forward-looking statements include statements about our expectations, beliefs, or \n intentions regarding our product offerings, business, financial condition, results of \n operations, strategies or prospects. You can identify such forward-looking statements by the \n words “anticipates,” “expects,” “intends,” “impacts,” “plans,” “projects,” “believes,” \n “estimates,” “likely,” “goal,” “assumes,” “targets” and similar expressions and/or the use of \n future tense or conditional constructions (such as “will,” “may,” “could,” “should” and the like) \n and by the fact that these statements do not relate strictly to historical or current matters. \n Rather, forward-looking statements relate to anticipated or expected events, activities, trends \n or results as of the date they are made. Because forward-looking statements relate to \n matters that have not yet occurred, these statements are inherently subject to risks and \n uncertainties that could cause our actual results to differ materially from any future results \n expressed or implied by the forward-looking statements. These forward-looking statements \n are only predictions and reflect our views as of the date they are made with respect to future \n events and financial performance. Many factors could cause our actual activities or results to \n differ materially from the activities and results anticipated in forward-looking statements, \n including risks related to: our approach to discover and develop novel drugs, which is \n unproven and may never lead to efficacious or marketable products; our ability to fund and \n the results of further pre-clinical and clinical trials; obtaining, maintaining and protecting \n intellectual property utilized by our products; our ability to enforce our patents against \n infringers and to defend our patent portfolio against challenges from third parties; our ability \n to obtain additional funding to support our business activities; our dependence on third \n parties for development, manufacture, marketing, sales, and distribution of products; the \n successful development of our product candidates, all of which are in early stages of \n development; obtaining regulatory approval for products; competition from others using \n technology similar to ours and others developing products for similar uses; our dependence \n on collaborators; our short operating history and other risks identified and described in more \n detail in the “Risk Factors” section of the Company’s most recent Annual Report on Form 10- \n K and other filings with the SEC, all of which are available on our website. We undertake no \n obligation to update, and we do not have a policy of updating or revising, these forward- \n looking statements, except as required by applicable law.","bbox":{"left":0.098039,"top":0.101814,"width":0.804458,"height":0.610677}},{"text":"CONTACTS:","bbox":{"left":0.098039,"top":0.728708,"width":0.115388,"height":0.016927000000000025}},{"text":"Maria Yonkoski, Head of Investor Relations \n Beyond Air, Inc. \n Myonkoski@beyondair.net","bbox":{"left":0.098039,"top":0.761852,"width":0.375689,"height":0.05291200000000007}},{"text":"Corey Davis, Ph.D. \n LifeSci Advisors, LLC \n Cdavis@lifesciadvisors.com \n (212) 915-2577","bbox":{"left":0.098039,"top":0.830981,"width":0.24421700000000002,"height":0.07090400000000008}}],"images_bbox":[],"images_bbox_not_text_overlap":[]}